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Background: Fibrosing disorders of the lung, such as idiopathic pulmonary fibrosis, are characterized by progressive
extracellular matrix accumulation that is driven by myofibroblasts. The transcription factor megakaryoblastic leukemia-1
(MKL1) mediates myofibroblast differentiation in response to several profibrotic stimuli, but the role it plays in mediating
pulmonary fibrosis has not been fully elucidated. In this study, we utilized mice that had a germline deletion of MKL1
(MKL1 (−,-)) to determine the role that MKL1 plays in the development of bleomycin-induced pulmonary fibrosis.
Methods: Bleomycin or normal saline were intratracheally delivered to 9 to 12 week old female MKL1 (+,+) and MKL1
(−,-) mice. Mice were assessed for weight loss and survival to 28 days. Inflammatory responses were assessed through
bronchoalveolar lavage at days 3 and 7 post-treatment. The development of pulmonary fibrosis was characterized
using hydroxyproline assay and histological staining. MKL1 (+,+) and MKL1 (−,-) mouse lung fibroblasts were isolated
to compare morphologic, gene expression and functional differences.
Results: MKL1 (−,-) mice demonstrated increased survival, attenuated weight loss, and decreased collagen accumulation
compared to wild-type animals 28-days after intratracheal instillation of bleomycin. Histological analysis demonstrated
decreased trichrome, smooth muscle α-actin, and fibronectin staining in MKL1(−,-) mice compared to MKL1 (+,+) controls.
Differential cell counts from bronchoalveolar lavage demonstrated that there was attenuated neutrophilia 3 days after
bleomycin administration, but no difference at day 7. Isolated mouse lung fibroblasts from MKL1 (−,-) mice had decreased
contractility and deposited less fibronectin matrix compared to wild-type controls, suggesting a defect in key remodeling
functions.
Conclusions: Altogether, these data demonstrate that MKL1 plays a significant role in mediating the fibrotic response
to bleomycin injury. Loss of MKL1 attenuated early neutrophil influx, as well as myofibroblast-mediated remodeling.
Targeting MKL1 activity may therefore be a useful strategy in treating pulmonary fibrosis.
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Fibrosing disorders of the lung, such as idiopathic
pulmonary fibrosis, are characterized by progressive
extracellular matrix accumulation that is driven by
myofibroblasts [1-4]. We have previously reported that
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unless otherwise stated.transcription factors megakaryoblastic leukemia-1 (MKL1)
and serum response factor (SRF) [5-7]. MKL1 is regulated
by the actin cytoskeleton [4], and activates the transcription
factor SRF [8-10]. Additionally, MKL1 has been observed
to be required for myofibroblast differentiation in response
to mechanical signals, matrix stiffness, and profibrotic
G-protein coupled receptor agonists [11-13]. Furthermore,
our group has observed that signaling via protein kinase A
(PKA) can protect against bleomycin-induced pulmonary
fibrosis in mice, and that this protective effect is likely via
inhibition of MKL1/SRF in myofibroblasts [14,15]. In thisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of pulmonary fibrosis using mice with a germline defi-
ciency of MKL1 [16] in the bleomycin model of disease.
We report that MKL1-deficient mice have decreased
collagen accumulation and increased survival compared
to wild-type animals. These effects are due, in part, to
modulation of critical myofibroblast remodeling functions,
such as contractility and fibronectin matrix formation.
Methods
Animals
Wild-type (MKL1 (+,+)) and knock out (MKL1 (−,-))
C57BL/6 mice [16] were kindly provided by Dr. Eric
Olson (University of Texas-Southwestern). Mice were
housed under controlled illumination and temperature
with unlimited access to water and rodent laboratory chow.
All animal studies were done following the appropriate
University of Wisconsin-Madison Institutional Care and
Use Committee and the National Institutes of Health
guidelines using 9 to 13 week old female mice. Over
the course of the experiments, the animals were closely
monitored for overall health and activity, and their weight
was taken daily.
Bleomycin-induced pulmonary fibrosis
9 to 13 week old MKL1 (+,+) and MKL1 (−,-) female
mice were anesthetized with ketamine (100 mg/kg) and
xylazine (15 mg/kg) prior to delivering a single dose of
intratracheal bleomycin (2 unit/kg, Sigma-Aldrich Co.,
St. Louis MO) dissolved in 50 μL of 0.9% NaCl Irrigation
(Baxter, Madison, WI) via endotracheal intubation. Control
animals were given a single intratracheal dose of 50 μL of
0.9% NaCl solution. Bronchoalveolar lavage (BAL) was per-
formed on mice 3 or 7 days after bleomycin treatment,
while the lungs of mice euthanized 28 days after treatment
were used for the hydroxyproline assay (left lung) and
histology (right lung). The mice were anesthetized
using ketamine (150 mg/kg) and xylazine (22.5 mg/kg)
and exsanguinated via the carotid artery prior to removing
the lungs or BAL. Log-rank test was performed to analyze
the differences in survival between bleomycin-treated
MKL1 (−,-) and MKL1 (+,+) mouse groups.
Hydroxyproline assay
Hydroxyproline assay was performed as described before
[15,14]. Briefly, left lungs were isolated and homogenized
in 0.5 M glacial acetic acid, followed by drying overnight
at 60°C. Dried, whole lung homogenates then were
weighed and hydrolyzed in 6 N HCl for 24 hours at 110°C.
Triplicate-samples were incubated with citrate-acetate
buffer and chloramine T at room temperature (RT) for
20 min prior to adding Ehrlich’s solution and incubating
at 65°C for 1 hour. Sample absorbance was measured
at 550 nm once the samples had cooled to RT. Using astandard curve generated from trans-4-Hydroxy-L-proline
(Sigma-Aldrich), sample hydroxyproline content was deter-
mined. One-way ANOVA was performed to compare the
collagen accumulation in the lungs of bleomycin-treated
MKL1 (−,-) and MKL1 (+,+) mice.
Histology
Right lungs were inflated using formaldehyde and fixed
for 24–48 hours before being moved to 70% ethanol.
The lungs were sectioned and subjected to Masson’s
trichrome staining and immunostaining for smooth
muscle α-actin (α-SMA) or fibronectin. Secondary anti-
bodies conjugated to either HRP (immunohistochemical
images) or Alexafluor-488 (for quantitation of α-SMA)
were utilized. The modified Ashcroft scale was used to
quantify fibrosis, as previously described [17]. Quantitation
of α-SMA immunostaining was performed by taking 10
images at 20X magnification per sample, using identical
exposure times and thresholds on an Olympus 1X71
fluorescent microscope and Q imaging Retiga 2000R
camera. ImageJ was used to measure integrated density of
the fluorescent signal [18]. Quantitation of fibronectin
histology was performed by taking a 2X magnification
image of each sample, using identical exposure times
and thresholds on an Olympus SZH10 microscope and
Olympus DP70 camera. ImageJ Immunohistochemistry
Toolbox plugin was utilized to isolate the brown stain
[19]. The resulting image was inverted, the lung was out-
lined and integrated density measured. Integrated density
measurement was divided by the total area of the lung in
order to account for differences in lung sizes.
Bronchoalveolar lavage
3 or 7 days following intratracheal bleomycin or 0.9%
NaCl treatment, BAL was performed. The mice were
anesthetized and exsanguinated as described above. The
trachea was then exposed and a catheter was used to
intubate the mice. The lungs were lavaged 5 times
using 1 ml of 0.9% NaCl. The BAL fluid was collected, cen-
trifuged at 400 g for 10 min, the total cells in the pellet
were counted and cytospins containing 7.5 x 105 cells/slide
prepared. Cytospins were stained using Wright Giemsa
stain (Fisher Scientific, Kalamazoo, MI) and then counted
noting the ratio of neutrophils, macrophages, lymphocytes
and eosinophils out of 500 total cells. One-way ANOVA
was performed to compare the number of each cell type
between treatment groups.
Isolation of mouse lung fibroblasts
Mouse lung fibroblasts were derived as previously described
[5] and in accordance with established methodology [20].
Briefly, following extraction, the lung was immediately
placed in cell maintenance medium: Dulbecco’s Modified
Eagle Medium (DMEM) + L-glutamine (Corning Inc.,
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Scientific, Waltham, MA), penicillin/streptomycin/ampho-
tericin (PSA, 1%, Mediatech, Herndon, VA), Ciprofloxacin
(1%, Corning Inc.) and L-glutamine (1%, Thermo Scientific).
After several rinses, the lung was minced, washed in media
and plated to attach. The media was replaced twice weekly
until 80-90% fibroblast confluence was reached at which
point the cells were trypsinized and passaged or utilized for
studies. Negative cell staining for E-cadherin confirmed no
contamination with epithelial cells. For experiments, cells
were grown in 6-well plates at a density of 2 x 105 cells/well
for 24 hours, placed in starvation medium (maintenance
medium with 10% FBS replaced by 0.1% bovine serum albu-
min (BSA)) for 24 hours. For indicated experiments, cells
were treated with 1 ng/ml Transforming Growth Factor-β
(TGF-β) (EMD Biosciences, Gibbstown, NJ) for the indi-
cated times prior to being subjected to gel contraction assay
or deoxycholate extraction.
Immunofluorescent staining
Mouse lung fibroblasts (MLF) were washed with tris
buffered saline (TBS), fixed for 30 min at RT using 4%
paraformaldehyde in TBS, permeabilized for 5 min at
RT using 0.2% Triton X-100 in TBS and blocked for
1 hour at RT in 10% Normal Goat Serum (NGS, Jackson
Laboratory, Bar Harbor, ME), 1% BSA in TBS. The cells
were incubated overnight at 4°C with the relevant primary
antibody, washed with TBS and incubated for 75 min at
37°C with appropriate secondary antibody conjugated to
fluorescein isothiocyanate (FITC, Pierce, Thermo Fisher,
Rockford, IL). They were then washed and if required
incubated with rhodamine phalloidin (Invitrogen, Carlsbad,
CA) for 30 min at RT. Cells were counterstained with
DAPI in TBS (0.42 μg/ml, Sigma-Aldrich) for 10 min at
RT, washed and mounted using Vectashield mounting
medium (Vector Labs, Burlingame, CA). Olympus 1X71
fluorescent microscope and Q imaging Retiga 2000R
camera were used to obtain immunofluorescent images.
To quantify focal adhesion length, 20 images at 60x
magnification were taken per cell type and the length
of vinculin stained focal adhesions was measured using
ImageJ.
Western blot
Cells were lysed in radioimmunoprecipitation assay (RIPA)
buffer containing 25 mM HEPES (pH 7.5), 150 mM NaCl,
1% Triton-X 100, 0.1% SDS, 2 mM EDTA, 2 mM EGTA,
10% glycerol, 1 mM NaF, 200 μM Na-orthovanadate,
1 mM Na-phyrophosphate, 1 mM β-glycerol phosphate
and protease inhibitor cocktail (Thermo-Scientific) for
10 min on ice. Next, cells were scraped, sonicated for
5 sec and centrifuged at 21.1 g for 10 min at 4°C. The
supernatant was then mixed with Laemmli buffer and
boiled for 5 min. The samples were electrophoresed onpolyacrylamide gels at 150 V for 1 hour and transferred at
100 V for 1 hour. Western blot was run with desired
primary antibodies and corresponding HRP-conjugated
secondary antibodies. The blots were developed by an
enhanced chemiluminescence (ECL) reaction (Pierce).
GE LAS4000 chemiluminescence imager was used to ob-
tain images below the saturation threshold. Densitometry
of selected blots was performed using ImageGuage
software (GE).
Gel contraction assay
MLF were trypsinized and seeded in a 4 mg/mL rat-tail
collagen solution (BD Biosciences, San Jose, CA) at a
density of 3 x 105 per mL in a 12-well plate. Gels were
allowed to solidify, then released from the plate and
allowed to contract in serum-free medium. Reduction of
gel diameter was calculated in each condition using ImageJ.
Deoxycholate (DOC) extraction
To determine the amount of fibronectin that is fully
incorporated into the extracellular matrix by MLF, we
assessed the amount of fibronectin that was resistant to
deoxycholate extraction, as per established methodology
[21]. Briefly, MLF (1 x 105 per ml) were plated in 10 cm
dishes for 24 hours in cell maintenance medium. Cells
were then starved for 24 hours in starvation medium and
treated with TGF-β (1 ng/mL) for 24 hours. Monolayers
were washed and scraped into 2% DOC in TBS, 2 mM
EDTA, 2 mM PMSF and protease inhibitor cocktail
(Thermo-Scientific). Extracts were centrifuged at 21.1 g for
15 min at 4°C. DOC-soluble material was removed, and
SDS-PAGE sample buffer (0.5 M Tris pH 6.8, 2% SDS, 10%
glycerol) was added with and without the addition of
β-mercaptoethanol and 10 mM DTT to reflect reduced or
unreduced conditions. DOC-insoluble material was
resuspended in solubilization buffer (1% SDS in TBS,
2 mM EDTA, 2 mM PMSF and protease inhibitors)
and treated with sample buffer as described above.
All samples were boiled for 5 minutes prior to being
subjected to polyacrylamide gel electrophoresis on 8%
gels and Western blotting.
Reverse transcription quantitative real time PCR
Real time PCR was carried out as previously described [7].
Briefly, left lungs were pulverized over dry ice and 100 mg
of tissue lysed in 1 ml RNA STAT-60 (AMS Biotechnology)
to extract total RNA. 1 μg of total RNA was used as a
template for random-primed reverse transcription using an
iScript cDNA synthesis kit (Bio-Rad). Real time PCR
analysis was performed using iTaq SYBR Green supermix
with ROX (Bio-Rad) in an ABI 7500 multi-color real time
PCR detection system (Applied Biosystems). PCR primers
for MKL2 (also known as MRTFB) were CCCCAGCAG
TTTGTTGTTCAGCACTCTT (forward) and GATGCTG
Bernau et al. Respiratory Research  (2015) 16:45 Page 4 of 11GCTGTCACTGGTTTCATCTTG (reverse), for α-SMA
were AAACAGGAATACGACGAAG (forward) and CAG
GAATGATTTGGAAAGGA (reverse), for FN were AGAC
CATACCTGCCGAATGTAG (forward) and GAGAGCTT
CCTGTCCTGTAGAG (reverse), and for Collagen
1α1 were ATGTTCAGCTTTGTGGACCT (forward) and
CAGCTGACTTCAGGGATGT (reverse).
Antibodies
Rabbit monoclonal antibody against α-SMA (for histological
staining) was from Abcam (Cambridge, UK). Polyclonal
rabbit antibody against fibronectin was a generous gift from
Dr. Deane Mosher at the University of Wisconsin-Madison.
Mouse monoclonal antibodies against α-tubulin, α-SMA
and vinculin were from Sigma-Aldrich. Rabbit polyclonal
antibody against total fibronectin was from Abcam. Mouse
monoclonal antibody against GAPDH was from Santa Cruz
Biotech (Santa Cruz, CA). Rabbit polyclonal antibody
against total MKL1 was from Bethyl (Montgomery, TX).
Mouse monoclonal antibody against E-Cadherin was from
BD Biosciences (San Jose, CA).
Statistics
One-way ANOVA was utilized to compare differences
between group means for continuous variables. For survival
data, we utilized the log-rank test.
Results
MKL1 is essential for the development of
bleomycin-induced pulmonary fibrosis
We first explored the effects that MKL1 germline deletion
has on the bleomycin-induced model of pulmonary
fibrosis. Since MKL1/SRF are known mediators of
myofibroblast differentiation [5-7], we hypothesized
that loss of MKL1 would attenuate pulmonary fibrosis.
Following treatment with bleomycin, MKL1 (+,+) and
MKL1 (−,-) mice’ weights were monitored daily. We
found that while the average MKL1 (+,+) animal weight
decreased to approximately 80% of their initial weight,
MKL1 (−,-) mice had similar initial weight loss, but then
began to regain weight from the second week after
bleomycin administration, correlating with the typical
onset of the fibrotic response (Figure 1A). Furthermore,
there was a significant difference in animal survival
between the two groups, with less than 80% of MKL1
(+,+) animals surviving 28-days post bleomycin treatment
in contrast to 100% survival of MKL1 (−,-) mice (Figure 1B).
We then assessed total fibrosis at 28 days using the
hydroxyproline assay to estimate collagen accumulation.
Bleomycin-treated MKL1-deficient mice had significantly
less collagen accumulation compared to wild-type controls
(Figure 1C), while overall dry lung weights were similar
between the groups (Figure 1D). We noted slightly lower
levels of hydroxyproline content in MKL1 (+,+) versusMKL1 (−,-) mice not treated with bleomycin, but this was
likely due to slightly smaller lungs in the knockout group
(Figures 1C, D, bar 2). To determine whether there were
potential basal differences in extracellular matrix gene
expression between MKL1 (+,+) mice and MKL1 (−,-)
mice, we assessed mRNA levels of fibronectin and collagen
1α1 in whole lungs of uninjured animals. As shown in
Figure 1E, there were no significant differences in the basal
expression of these genes between uninjured MKL1 (+,+)
or MKL1 (−,-) lungs. In contrast, the expression of smooth
muscle α-actin (α-SMA), a known target of MKL1, was
significantly attenuated in uninjured MKL1 (−,-) mice.
Notably, the expression of MKL2, which shares some
signaling overlap with MKL1, was not significantly changed
in MKL1 (−,-) mice, compared to wild type controls. These
data demonstrate that MKL1 plays an important role in
mediating the fibrotic response to bleomycin, while being
dispensable for the expression of fibronectin and collagen
1α1 (but not of α-SMA) in uninjured lungs.
Trichrome staining of mouse lungs at 28 days was con-
sistent with the observed decrease in bleomycin-induced
collagen accumulation seen in MKL1 (−,-) mice (Figure 2A).
Fibrosis scoring of these slides, using modified Ashcroft
scores [17], demonstrated a reduction in the fibrotic
response to bleomycin in MKL1 (−,-) mice (Figure 2A,
right panel). To assess the expansion of myofibroblasts in
the lungs during bleomycin fibrosis, we utilized α-SMA
staining. The lungs from bleomycin-treated MKL1 (+,+)
mice had significantly more α-SMA staining compared to
MKL1 (−,-) mice 28 days post bleomycin injury (Figure 2B).
Fibroblast-mediated deposition of a fibronectin matrix is
required for the formation of a collagen matrix [22,23].
Thus, to assess for de novo matrix accumulation, we
stained for cellular fibronectin, which demonstrated
decreased staining in bleomycin-treated MKL1 (−,-)
mice compared to the wild-type controls (Figure 2C).
Together, these results further indicate that MKL1
attenuates fibrosis following bleomycin treatment, possibly
via inhibition of myofibroblast expansion and fibronectin
matrix formation.
MKL1 mediates neutrophilic inflammation and tissue
injury in response to bleomycin
Considering that the response to intratracheal bleomycin
delivery is initially characterized by injury followed by
neutrophilic inflammation [24-27], we sought to determine
whether the early response to bleomycin was modified by
MKL1. To evaluate this possibility, BAL was performed at
3 and 7 days following bleomycin or saline treatment.
Interestingly, overall BAL cell counts were attenuated in
bleomycin-treated MKL1 (−,-) mice compared to MKL1
(+,+) controls at day 3 (Figure 3A). Bleomycin-induced
neutrophilia was evident, as expected, in wild-type
animals [25,24], however, there appeared to be attenuated
Figure 1 MKL1 (−,-) mice demonstrate increased survival and decreased collagen accumulation following experimentally-induced
fibrosis compared to MKL1 (+,+) controls. A. Comparison of fraction of original weight over time (up to day 28) for MKL1 (+,+) and MKL1
(−,-) mice. B. Percent survival of MKL1 (+,+) and MKL1 (−,-) animals over time (up to day 28). Log-rank test (p < 0.05) was used to assess statistical
significance. C. Quantitation of collagen accumulation in the left lung of MKL1 (+,+) and MKL1 (−,-) animals 28 days following saline or bleomycin
treatment using hydroxyproline assay. D. Left lung dry weights of MKL1 (+,+) and MKL1 (−,-) animals treated with either normal saline or bleomycin.
E. mRNA expression of MKL2, α-SMA, fibronectin and collagen1α1 in MKL1 (+,+) and MKL1 (−,-) untreated mouse lungs. One-way ANOVA (p < 0.05)
was used to test for statistical significance.
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mice at day 3 (Figure 3B). Most of this difference was
related to the drop in total cell count in MKL1 (−,-) mice,
as differential counts of BAL cells did not reveal sig-
nificant differences in the percentage of neutrophils,
macrophages, lymphocytes or eosinophils between
bleomycin-treated MKL1 (−,-) and MKL1 (+,+) mice
(Figure 3D). To determine if changes in neutrophilia
correlated with tissue injury, we assessed histologic
changes via Ashcroft score. As shown in Figure 3C,
there were no significant differences between MKL1
(+,+) and MKL1 (−,-) mice at day 3. By day 7, total lavage
cell counts had risen further in bleomycin-treated animals
and there was no difference in total cell counts between
MKL1 (+,+) mice and MKL1 (−,-) mice (Figure 3E).
We also did not observe a significant difference in
neutrophilic inflammation by absolute neutrophil
count or by percentage of BAL cells (Figure 3F and H).
Likewise, the amount of lymphocytic inflammation
was unaltered (Figure 3H). However, Aschroft scoring ofbleomycin-injured lungs at day 7 demonstrated attenuation
in tissue injury and fibrosis in MKL1 (−,-) mice compared
to wild-type controls (Figure 3G). Taken together, these
data suggest that MKL1 may impact the early neutrophilic
response to bleomycin. By day 7, these early differences in
BAL neutrophilia have resolved, but MKL1 (−,-) mice
display evidence of attenuated tissue injury and fibrosis in
response to bleomycin.
MKL1 is required for contractile functions in fibroblasts
The formation of a myofibroblast population during
bleomycin pulmonary fibrosis is due to expansion and
activation of resident lung fibroblasts [28-30]. Given the
observed decrease in myofibroblasts seen in Figure 2, we
sought to investigate the effects that MKL1 knockout
has on primary mouse lung fibroblasts (MLF) ex vivo.
Upon culturing in either a 2D or 3D system, MKL1 (−,-)
MLF do not attain the typical spindle appearance that
characterizes fibroblasts (Figure 4A). Rather the cells
have a rounded, “epithelioid” morphology. Furthermore,
Figure 2 MKL1 (−,-) mouse lungs following experimentally-induced fibrosis have decreased collagen, α-SMA and fibronectin accumulation
compared to MKL1 (+,+) controls. A. Trichrome staining of MKL1 (+,+) and MKL1 (−,-) mouse lungs following bleomycin or saline treatment
denoting areas of collagen accumulation (blue) with the corresponding modified Ashcroft score for each condition. B. Immunohistochemical staining
for α-SMA (brown) and C. fibronectin (brown) including their respective quantitation. One-way ANOVA (p < 0.05) was used for statistical significance.
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decreased expression of the contractile gene α-SMA
compared to MKL1 (+,+) MLF (Figure 4B), while fibro-
nectin expression (two bands in Figure 4B represent-
ing two splice isoforms) appeared to be unaffected.
Immunofluorescent co-staining of the actin cytoskeleton
with phalloidin (red) and vinculin (green) revealed a
decreased number and complexity of actin stress fibers in
MKL1 (−,-) MLF as compared to MKL1 (+,+) controls
(Figure 4C, rhodamine phalloidin stain, right image).
Likewise, vinculin staining demonstrated smaller, morediscrete focal adhesions (FA) by MKL1 (−,-) MLF in
comparison to MKL1 (+,+) (Figure 4C, green stain,
right image). This was confirmed through FA length
analysis (vinculin staining) using ImageJ, showing that
MKL1 (−,-) MLF indeed have shorter adhesions com-
pared to MKL1 (+,+) MLF (Figure 4D). Functionally,
MKL1 (−,-) cells demonstrated a defect in contraction of
collagen gels, under basal conditions or after treatment
with the profibrotic cytokine TGF-β for 72 hours
(Figure 4E). Gel contraction quantification revealed a sig-
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Figure 3 The early inflammatory response to bleomycin does not differ between MKL1 (+,+) and MKL1 (−,-) mice. A. Total BAL cell
counts obtained 3 days following intratracheal saline or bleomycin treatment in MKL1 (+,+) and MKL1 (−,-) mice. B. Absolute neutrophil counts
from the day 3 BALs obtained in Figure 3A. C. Modified Ashcroft scores from trichrome-stained MKL1 (+,+) and MKL1 (−,-) mouse lungs done
3 days after bleomycin treatment. D. BAL differential cell counts of the same day 3 groups as in Figure 3A, depicting the percentage of neutrophils,
macrophages, lymphocytes and eosinophils counted following saline and bleomycin treatment in MKL1 (+,+) and MKL1 (−,-) mice. E. Total BAL cell
counts obtained 7 days following intratracheal saline or bleomycin treatment in MKL1 (+,+) and MKL1 (−,-) mice. F. Absolute neutrophil counts from
the day 7 BALs obtained in Figure 3E. G. Modified Ashcroft scores from trichrome-stained MKL1 (+,+) and MKL1 (−,-) mouse lungs done 7 days after
bleomycin treatment. H. BAL differential cell counts of the same day 7 groups as in Figure 3E, depicting the percent of neutrophils, macrophages,
lymphocytes and eosinophils counted following saline and bleomycin treatment in MKL1 (+,+) and MKL1 (−,-) mice. One-way ANOVA (p < 0.05) was
performed to test for statistical significance.
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(Figure 4E, right panel). This effect is likely due to the loss
of α-SMA expression (as in Figure 4B), which is critical for
contractile force generation [31].We then sought to determine whether key matrix
remodeling functions of the fibroblast are affected by
MKL1. Assembly of a mature, deoxycholate-insoluble
fibronectin matrix is a key step in the formation of
TGF-  (72 hrs)
A
C MKL1 (+,+) MKL1 (-,-)
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Figure 4 MKL1 is required for contractile functions of the myofibroblast. A. Phase contrast microscopy of representative MKL1 (+,+) and
MKL1 (−,-) primary mouse lung fibroblasts (MLF) grown on 2D plates (top row) and 3D in collagen (bottom row) to show morphological
differences. B. MKL1 (+,+) and MKL1 (−,-) primary MLF lysates were analyzed by Western blot with antibodies against fibronectin (FN), vinculin,
α-SMA and α-tubulin. Densitometry of n = 3 experiments (bottom panel). C. Merged images of 2D primary MLF subjected to immunofluorescent
staining with phalloidin rhodamine (red) and or primary antibodies directed against vinculin and FITC-conjugated secondary antibodies (green).
D. Cells stained by indirect immunofluorescence against vinculin were analyzed for focal adhesion size by quantitation of vinculin plaque length
using ImageJ (as described in methods). E. MKL1 (+,+) and MKL1 (−,-) primary MLF were treated with 1 ng/ml TGF-β (72 hrs) or vehicle control
prior to plating into 3D collagen gels for gel contraction assessment over 2 days. Gel areas were quantified from the digital images using ImageJ
(right panel). F. MKL1 (+,+) and MKL1 (−,-) MLF were plated, serum-starved and stimulated with 1 ng/ml TGF-β or vehicle control for 24 hours.
Cells were subjected to deoxycholate (DOC) extraction, with DOC-soluble and DOC-insoluble lysates subjected to gel electrophoresis under
reducing (first panel) and non-reducing (second panel) conditions followed by Western blotting for total fibronectin. Fibronectin bands from
both soluble and insoluble lysates were quantified by densitometry and values expressed as the ratio of insoluble to soluble fibronectin (third panel).
One-way ANOVA (p < 0.05) was performed to test for statistical significance.
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formation of a deoxycholate (DOC)-insoluble fibronectin
matrix in wild-type cells (Figure 4F, middle panel), as well
as an increase in unincorporated, soluble fibronectin(Figure 4F, left panel). Under treatment with TGF-β,
MKL1 (−,-) fibroblasts still manifest an increase in
available soluble fibronectin (Figure 4F, left panel, lane
4, top band), but there is a loss of incorporation of
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(Figure 4F, middle panel, lane 4). Quantitation of the
ratio of DOC-insoluble matrix to DOC soluble matrix for
MKL1 (+,+) and MKL1 (−,-) cells (Figure 4F, right panel),
shows a reduction in the formation of a mature, DOC-
insoluble fibronectin matrix by MKL1 (−,-) MLF under
basal and TGF-β-stimulated conditions. Thus, despite an
ability to express fibronectin, MKL1 (−,-) fibroblasts appear
to have a defect in the ability to form a mature extracellular
fibronectin matrix. This is also likely due, in part, to the
loss of α-SMA expression which is required for the proper
assembly and deposition of fibronectin [33,34]. Overall,
these results show that MKL1 is required for main-
taining both a contractile phenotype and key contraction-
dependent remodeling functions in fibroblasts.
Discussion
The present study demonstrates a key role of MKL1 in
the development of pulmonary fibrosis in the bleomycin
model of disease. Our results are consistent with the
findings from other groups supporting a role for MKL1
in cardiac fibrosis [35] and in collagen accumulation in
the lung in response to bleomycin [36]; and we further
elaborate on the mechanism of the pro-fibrotic role of
MKL1. Given the role that MKL1 plays in mediating
myofibroblast differentiation, our primary hypothesis was
that loss of MKL1 would impair myofibroblast-driven
responses to bleomycin-injury. However, MKL1/SRF has
also been shown to control neutrophil migration
[37], lymphocyte maturation [38], and megakaryocyte
maturation [39-41], each of which could modify the
response to bleomycin. In fact, we did observe that
MKL1 may facilitate the early neutrophilic response to
bleomycin, as MKL1 (−,-) mice had less BAL neutrophilia
at day 3 post-bleomycin administration. However,
differences in BAL neutrophilia had resolved by day
7. In contrast to the observed changes in early BAL
neutrophilia, we did not observe significant differences
in other inflammatory cell counts at either day 3 or
7. Interestingly, while we did not see meaningful
differences in tissue injury at day 3, we did observe
significant changes in fibrosis score occurring by day
7 post-bleomycin administration. This suggests that the
attenuated early neutrophilic response may translate to
decreased tissue injury at early timepoints in MKL1 (−,-)
mice. Despite these observations, it is important to note
that the initial physiologic response to bleomycin during
the early inflammatory phase is similar between the two
groups, as MKL1 (−,-) mice experienced weight loss that
initially paralleled their wild-type littermate controls.
Weights began to diverge between the two populations
around the second week, which coincides with the onset
and peak of the fibrotic phase [27,26]. This suggests
that modification of the fibrotic response is playingan important role in the protection seen in MKL1 (−,-)
mice. Supporting this concept, markers of fibrosis, such as
hydroxyproline content, myofibroblast expansion, and
fibronectin matrix formation were all attenuated in the
MKL1-deficient mice.
Our ex vivo experiments suggest that the attenuation
in fibrosis seen in MKL1 (−,-) mice appears to be directly
related to alterations in contractile gene expression,
contractile force generation and the formation of a mature
fibronectin matrix in MKL1 (−,-) fibroblasts. Taken together,
these data suggest that the primary defect in MKL1
(−,-) animals is that of impaired fibroblast remodeling
functions leading to a decreased amount of fibrosis.
Notably, MKL1 (−,-) mice have also been observed to
have defects in lactation, due to loss or dysfunction
of myoepithelial cells, contractile cells that are similar
to myofibroblasts [16,42]. The observed loss of the
contractile gene α-SMA in MKL1 (−,-) fibroblasts
may be critical, as loss of α-SMA also results in failure of
lactation [43,44] and we have recently reported that
myofibroblast-mediated fibronectin matrix assembly re-
quires expression of α-SMA [33]. Our work lends further
support to the importance of contractile gene expression
by myofibroblasts in mediating their function. An
additional component to the attenuation of fibrosis seen
in MKL1 (−,-) mice could be the loss of anti-apoptotic
signaling via the SRF-dependent gene, BCL2 [45] or
attenuated expression of collagen isoforms [35,46].
For example, potentiation of myofibroblast apoptosis via
attenuation of BCL2 expression has been postulated in
mediating the protective effect of the ROCK inhibitor
fasudil in the bleomycin model [36]. These mechanisms
would be expected to add to the defects in fibroblast
remodeling functions that we observed in this model.
In our studies, the protective response of MKL1 germ-
line deletion appears to be partial. We hypothesize that
this could be explained by compensatory signaling via
MKL2, a homologue of MKL1 which can also mediate
activation of SRF-dependent genes and myofibroblast
differentiation [47,48,13]. MKL2 compensatory signaling
in MKL1-null animals has been previously reported in dif-
ferentiation of other cell types, supporting this hypothesis
[39]. Importantly, we did not see any upregulation of
MKL2 levels in MKL1 (−,-) mice (Figure 1E), but redun-
dant signaling through MKL2 could still partially compen-
sate for loss of MKL1. Unfortunately, germ-line deletion
of MKL2 cannot be explored in the bleomycin model due
to embryonic lethality [49,50].
Inhibition of MKL1-dependent signaling is potentially
attractive given its role as an integrator of several profibro-
tic inputs [4], and the potential for preservation of
TGF-β signaling that may serve a homeostatic role
[51,52]. Nuclear localization of MKL1 is controlled by
actin dynamics, under the control of Rho-kinase (ROCK)
Bernau et al. Respiratory Research  (2015) 16:45 Page 10 of 11[10] and ROCK is required for bleomycin-induced pul-
monary fibrosis [53,36]. Thus, the protective effect of
MKL1 germline deletion we have observed is consistent
with a vital role for the ROCK/MKL1 signaling axis in the
fibrotic response. However, ROCK signaling is pleotropic
and can also be involved in regulating Smad [54,55] and
MAP kinase signaling [56,57], suggesting that these two
molecules do not have completely overlapping effects.
Furthermore, although the protective effect of MKL1 dele-
tion is likely due, in large part, to loss of SRF-dependent
gene expression during fibrosis, we cannot completely
exclude contributions from Smad-dependent genes, given
the reported interaction of Smads and MKL1 [58]. Thus,
future approaches that utilize tissue-restricted deletion of
MKL1 or SRF in adult animals may better clarify the best
approach to disrupting this signaling axis.
Conclusions
Altogether, our study indicates that MKL1/SRF may
play a significant role in neutrophil influx, myofibro-
blast differentiation, and lung fibrosis in response to bleo-
mycin, as MKL1-deficient mice demonstrate decreased
evidence of collagen accumulation and increased survival
compared to wild-type controls. Our ex vivo analysis con-
firms that attenuated lung fibrosis is due, in part, to MKL1’s
critical role in myofibroblast remodeling functions, such as
fibronectin incorporation and contractile force generation.
In light of this, targeting MKL1/SRF may be a useful strategy
for disrupting myofibroblast function during pulmonary
fibrosis.
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